Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: A retrospective review

Melanoma Research

Volumn 24, Issue 4, 2014, Pages 349-353

  Dzienis, Marcin R ^a   Atkinson, Victoria G ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

B RAF kinases; brain neoplasms; melanoma; metastatic; response rate; treatment outcome; vemurafenib

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LOCAL THERAPY; MALE; MELANOMA; METASTATIC MELANOMA; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION; AGED; BIOSYNTHESIS; BRAIN NEOPLASMS; ENZYMOLOGY; METASTASIS; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; SURVIVAL; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84904060551     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000068     Document Type: Article

References (24)

1. AIHW. Cancer in Australia 2012: an overview. Cancer series no. 74. Cat. no. CAN 70. Canberra: Australian Institute of Health and Welfare; 2012.
2. AIHW.Australia's health 2010. Australia's health no. 12. Cat. no. AUS 122. Canberra: Australian Institute of Health and Welfare; 2010.
3. Australian Bureau of Statistics. 3303.0 Causes of death, Australia, 2010. Table 4.1 Underlying causes of death, all causes. Queensland: Australian Bureau of Statistics; 2010.
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009; 27:6199-6206.
5. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11-20.
6. Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer 1988; 61:1926-1934.
7. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 2009; 16:248-255.
8. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978; 42:660-668.
9. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomised trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500.
10. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300.
11. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998; 42:581-589.
12. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared to dacarbazine in patients with disseminated malignant melanoma; a phase III study. J Clin Oncol 2004; 22:1118-1125.
13. Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006; 17:1592-1597.
14. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma. J Clin Oncol 2004; 22:2101-2107.
15. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an openlabel, phase 2 trial. Lancet Oncol 2012; 13:459-465.
16. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with VAl600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
18. Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 2008; 15:25-45.
19. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
20. Bachelot T, Romieu G, Campone M, Dié ras V, Cropet C, Dalenc F, et al. Lapatinib and capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14:64-71.
21. Harding JJ, Catalanotti F, Yaqubie A, McDermott GC, Kersellius R, Merghoub T, et al. Vemurafenib in patients with BRAF-mutant melanoma and brain metastases [abstract]. J Clin Oncol 2013; 31:9060.
22. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiotherapy for patients with brain metastasis from metastatic melanoma. Cancer 2008; 113:2139-2145.
23. Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006; 76:59-64.
24. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-1703.